نتایج جستجو برای: naloxone hydrochloride

تعداد نتایج: 48808  

2018
Jeffrey T. Lai Brittany P. Chapman Katherine L. Boyle Edward W. Boyer Peter R. Chai

Opioid overdose is a growing public health emergency in the United States. The antidote naloxone must be administered rapidly after opioid overdose to prevent death. Bystander or "take-home" naloxone programs distribute naloxone to opioid users and other community members to increase naloxone availability at the time of overdose. However, data describing the natural history of take-home naloxon...

Journal: :Anesthesiology 2002
Thomas Peter Weber Andreas Meissner Jörg Stypmann Maike Grosse Hartlage Hugo Van Aken Norbert Rolf

BACKGROUND In patients undergoing colonoscopy, naloxone has vasodilative properties. However, it remains unclear whether this effect is mediated by central or peripheral mechanisms. The aim of this study was to investigate whether these effects are mediated by an effect of naloxone on the central nervous system. METHODS Twenty dogs were chronically instrumented for measurement of hemodynamic ...

Journal: :BMC Public Health 2021

Abstract Background Opioid related overdoses and overdose deaths continue to constitute an urgent public health crisis. The implementation of naloxone programs, such as ‘take-home naloxone’ (THN), has emerged a key intervention in reducing opioid deaths. These programs aim train individuals at risk witnessing or experiencing recognize respond with naloxone. Naloxone effectively reverses on phys...

2017
BT Gufford GR Ainslie JR White ME Layton JM Padowski GM Pollack MF Paine

Easy-to-use naloxone formulations are needed to help address the opioid overdose epidemic. The pharmacokinetics of i.v., i.m., and a new i.n. naloxone formulation (2 mg) were compared in six healthy volunteers. Relative to i.m. naloxone, geometric mean (90% confidence interval [CI]) absolute bioavailability of i.n. naloxone was modestly lower (55%; 90% CI, 43-70% vs. 41%; 90% CI, 27-62%), where...

Journal: :Addiction 2009
Debra Kerr Anne-Maree Kelly Paul Dietze Damien Jolley Bill Barger

AIMS Traditionally, the opiate antagonist naloxone has been administered parenterally; however, intranasal (i.n.) administration has the potential to reduce the risk of needlestick injury. This is important when working with populations known to have a high prevalence of blood-borne viruses. Preliminary research suggests that i.n. administration might be effective, but suboptimal naloxone solut...

Journal: :The American journal on addictions 2004
Leslie Amass Walter Ling Thomas E Freese Chris Reiber Jeffrey J Annon Allan J Cohen Dennis McCarty Malcolm S Reid Lawrence S Brown Cynthia Clark Douglas M Ziedonis Jonathan Krejci Susan Stine Theresa Winhusen Greg Brigham Dean Babcock Joan A Muir Betty J Buchan Terry Horton

In October 2002, the U.S. Food and Drug Administration approved buprenorphine-naloxone (Suboxone) sublingual tablets as an opioid dependence treatment available for use outside traditionally licensed opioid treatment programs. The NIDA Center for Clinical Trials Network (CTN) sponsored two clinical trials assessing buprenorphine-naloxone for short-term opioid detoxification. These trials provid...

Journal: :Anesthesiology 1989
Eveline van Dorp Ashraf Yassen Elise Sarton Raymonda Romberg Erik Olofsen Luc Teppema Meindert Danhof Albert Dahan

BACKGROUND The objective of this investigation was to examine the ability of the opioid antagonist naloxone to reverse respiratory depression produced by the mu-opioid analgesic, buprenorphine, in healthy volunteers. The studies were designed in light of the claims that buprenorphine is relatively resistant to the effects of naloxone. METHODS In a first attempt, the effect of an intravenous b...

Journal: :Molecular cancer therapeutics 2006
Mariya Farooqui Zhen H Geng Elliot J Stephenson Nurulain Zaveri Douglas Yee Kalpna Gupta

Estrogen promotes the growth of breast cancer via estrogen receptors (ER). Earlier studies showed that the opioid receptor antagonist naloxone inhibits MCF-7 breast cancer growth in mice. We examined the cellular and molecular mechanism of naloxone antagonism of ERalpha activity in human MCF-7 cells. Naloxone (100 nmol/L) inhibited 17beta-estradiol (E2)-induced (10 nmol/L) MCF-7 cell proliferat...

Journal: :The journal of pain : official journal of the American Pain Society 2012
Susannah S Lewis Lisa C Loram Mark R Hutchinson Chien-Ming Li Yingning Zhang Steven F Maier Yong Huang Kenner C Rice Linda R Watkins

UNLABELLED Previous work demonstrated that both the opioid antagonist (-)-naloxone and the non-opioid (+)-naloxone inhibit toll-like receptor 4 (TLR4) signaling and reverse neuropathic pain expressed shortly after chronic constriction injury. The present studies reveal that the TLR4 contributes to neuropathic pain in another major model (spinal nerve ligation) and to long established (2-4 month...

Journal: :Scientia Pharmaceutica 2022

There is a need to develop dosage forms suitable for children improve drug treatment. Extemporaneous compounding of drugs one way meet these needs. However, excipients generally considered as safe in adults may not be appropriate intended children. The aim was optimize the composition two pediatric liquid preparations by substituting paraben microbiological preservative and ethanol solubilizer,...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید